Replimune Group, Inc. (REPL)

Replimune Group, Inc. (REPL) is a healthcare company (biotechnology) based in the United States. The share price is $20.44, down 4.55% on the day, which values the company at $1.94B. Price as of 17 Nov 2026, 17:31 UTC, from Yahoo Finance.

Key facts

Share price
$20.44−4.55% today
Market value
$1.94B
200-week average
$11.5976% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Replimune Group, Inc. in more detail

REPL trades at -30.5× next year's expected earnings. It sits 76% above its 200-week average of $11.59.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

2 of the superinvestors tracked here hold REPL, including Julian and Felix Baker (0.6% of the portfolio), Louis Bacon (0.4% of the portfolio).

Superinvestors holding REPL

2 of the investors tracked here report a position in their latest 13F filing.

Replimune Group, Inc. (REPL): questions and answers

What is Replimune Group, Inc.'s market cap?

Replimune Group, Inc. is valued at $1.94B at a share price of $20.44.

Is REPL above its 200-week moving average?

Yes. REPL is 76.4% above its 200-week average of $11.59. Long-term investors watch that line because strong companies rarely trade below it for long.

Does REPL pay a dividend?

Replimune Group, Inc. does not currently pay a regular dividend.

Which famous investors own REPL?

In their latest quarterly filings, Julian and Felix Baker (0.6% of the portfolio), Louis Bacon (0.4% of the portfolio) hold REPL. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Replimune Group, Inc. (REPL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/REPL

Underlying data: Yahoo Finance; company filings with the SEC.